Quarterly report pursuant to Section 13 or 15(d)

REVENUES

v3.24.3
REVENUES
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUES

 NOTE 10 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:  

                 
   

Three months ended  

September 30, 

  
    2024   2023  
Zembrace Symtouch   $ 2,485   $ 3,292  
Tosymra     337     697  
Total product revenues   $ 2,822   $ 3,989  
                 
   

Nine months ended  

September 30, 

  
    2024   2023  
Zembrace Symtouch   $ 6,059   $ 3,292  
Tosymra     1,453     697  
Total product revenues   $ 7,512   $ 3,989  

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $4.8 million at September 30, 2024, of which $1.0 million was recorded as a reduction to accounts receivable and $3.8 million was recorded as a component of accrued expenses.